ReviewFrontiers in immunology2021
Update Advances on C-Reactive Protein in COVID-19 and Other Viral Infections.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 141 citations in OpenAlex.
- Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.Stem cell research & therapy · 2023Trial
- Assessment of the relationship between CT-severity scores, pulmonary artery diameters, and D-dimer/CRP ratios in COVID-19 patients.Frontiers in medicine · 2026Article
- Metabolic reprogramming induced by CRP deficiency or human CRP transgenic in influenza-infected mice.Frontiers in immunology · 2026Article
- Diagnostic superiority of serial increase in C-reactive protein versus single measurement in differentiating bacterial from non-bacterial etiologies in pediatric patients.Paediatrics & child health · 2025Article
- Prediction of COVID-19 disease progression by multiparametric analysis of circulating extracellular vesicles with flow cytometry.Journal of virology · 2025Article
- Clinical efficacy of combined detection of serum procalcitonin and C-reactive protein in early differential diagnosis of bacterial and viral pneumonia and analysis of related inflammatory response mechanisms.Biomarkers in medicine · 2025Article
- Euthyroid Sick Syndrome as an Index of Prognosis in Severe COVID-19 Disease.Medicina (Kaunas, Lithuania) · 2025Article
- Predictive Performance of SAPS-3, SOFA Score, and Procalcitonin for Hospital Mortality in COVID-19 Viral Sepsis: A Cohort Study.Life (Basel, Switzerland) · 2025Article
- Integrating the Interleukins in the Biomarker Panel for the Diagnosis and Prognosis of Patients with Acute Coronary Syndromes: Unraveling a Multifaceted Conundrum.Diagnostics (Basel, Switzerland) · 2025Article
- Vitamin D Serum Levels and the Development of Intensive Care Unit-Acquired Weakness: Insights from a COVID-19 Intensive Care Cohort.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Analysis of six consecutive waves of ICU-admitted COVID-19 patients: key findings and insights from a Portuguese population.GeroScience · 2025Article
- Lymphocyte-C-reactive protein ratio upon admission to predict disease progression and ICU admission in adult patients with diabetic ketoacidosis.Scientific reports · 2025Article
- Severe COVID-19 induces prolonged elevation of the acute-phase protein pentraxin 3.Frontiers in immunology · 2025Article
- Immune dysregulation and endothelial dysfunction associate with a pro-thrombotic profile in Long COVID.Frontiers in immunology · 2025Article
- Respiratory infections in the post-COVID-19 era: impact, prevalence, and clinical characteristics of bacterial and viral co-infections.Frontiers in medicine · 2025Article
- Gut microbiome dysbiosis and inflammatory markers in severe COVID-19: links to atherosclerosis and potential therapeutic insights.Gastroenterology and hepatology from bed to bench · 2025Article
- Explainable machine learning model and nomogram for predicting the efficacy of Traditional Chinese Medicine in treating Long COVID: a retrospective study.Frontiers in medicine · 2025Article
- Recent updates of interferon-derived myxovirus resistance protein A as a biomarker for acute viral infection.European journal of medical research · 2024Review
- Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients.Journal of clinical medicine · 2024Article
- Interleukin-1 Beta rs16944 and rs1143634 and Interleukin-6 Receptor rs12083537 Single Nucleotide Polymorphisms as Potential Predictors of COVID-19 Severity.Pathogens (Basel, Switzerland) · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe coronavirus disease 2019 (COVID-19) can manifest as a viral-induced hyperinflammation with multiorgan dysfunction. It has been documented that severe COVID-19 is associated with higher levels of inflammatory mediators than a mild disease, and tracking these markers may allow early identification or even prediction of disease progression. It is well known that C-reactive protein (CRP) is the acute-phase protein and the active regulator of host innate immunity, which is highly predictive of the need for mechanical ventilation and may guide escalation of treatment of COVID-19-related uncontrolled inflammation. There are numerous causes of an elevated CRP, including acute and chronic responses, and these can be infectious or non-infectious in etiology. CRP are normally lacking in viral infections, while adaptive immunity appears to be essential for COVID-19 virus clearance, and the macrophage activation syndrome may explain the high serum CRP contents and contribute to the disease progression. Nevertheless, for the assessment of host inflammatory status and identification of viral infection in other pathologies, such as bacterial sepsis, the acute-phase proteins, including CRP and procalcitonin, can provide more important information for guiding clinical diagnosis and antibiotic therapy. This review is aimed to highlight the current and most recent studies with regard to the clinical significance of CRP in severe COVID-19 and other viral associated illnesses, including update advances on the implication of CRP and its form specifically on the pathogenesis of these diseases. The progressive understanding in these areas may be translated into promising measures to prevent severe outcomes and mitigate appropriate treatment modalities in critical COVID-19 and other viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.